You have 9 free searches left this month | to do more
Showing 1 - 25 of
272 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
Recruiting
  • Multiple Myeloma
  • Daratumumab
  • Cologne, Germany
    University of Cologne
2022-04-04
Apr 4, 2022
E
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Not yet recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • Daratumumab / Hyaluronidase Injection
  • (no location specified)
2022-03-11
Mar 11, 2022
D
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia
Not yet recruiting
  • Hemolytic Anemia
  • Daratumumab / Hyaluronidase Injection
  • (no location specified)
2022-03-15
Mar 15, 2022
M
Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease
Recruiting
  • Alzheimer Disease
  • Daratumumab Injection
  • Manhasset, New York
    The Litwin-Zucker Research Center
2021-11-16
Nov 16, 2021
S
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Withdrawn
  • Multiple Myeloma
  • Daratumumab
  • Charlotte, North Carolina
    Levine Cancer Institute
2022-03-25
Mar 25, 2022
J
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • Daratumumab
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-24
Feb 24, 2022
M
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
2021-12-22
Dec 22, 2021
J
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Part 1 (Dose Escalation): Daratumumab
  • +3 more
  • Boston, Massachusetts
  • +7 more
2022-03-24
Mar 24, 2022
P
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
Not yet recruiting
  • AL Amyloidosis
    • (no location specified)
    2022-03-15
    Mar 15, 2022
    C
    Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma - 2022
    Completed
    • Multiple Myeloma
    • Baltimore, Maryland
      The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    2022-03-09
    Mar 9, 2022
    A
    Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation
    Not yet recruiting
    • Plasma Cell Leukemia
    • Daratumumab
    • (no location specified)
    2021-09-22
    Sep 22, 2021
    T
    Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
    Recruiting
    • Multiple Myeloma
    • Lenalidomide Pill
    • +2 more
    • Indianapolis, Indiana
      VA Roudebush Medical Center
    2022-01-27
    Jan 27, 2022
    M
    Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
    • Charlotte, North Carolina
      Levine Cancer Institute
    2021-10-01
    Oct 1, 2021
    H
    Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • Daratumumab Injection
    • +3 more
    • Tampa, Florida
      H. Lee Moffitt Cancer & Research Institute
    2022-04-07
    Apr 7, 2022
    U
    Treatment of POEMS Syndrome With Daratumumab
    Recruiting
    • POEMS Syndrome
    • Daratumumab Injection
    • Little Rock, Arkansas
      University of Arkansas for Medical Sciences
    2021-08-02
    Aug 2, 2021
    B
    Daratumumab in Cardiac Allograft AMR & HLA Desensitization Prior to Transplantation
    Not yet recruiting
    • Antibody-mediated Rejection
    • Cardiac Transplant
    • Daratumumab and hyaluronidase-fihj
    • Rochester, Minnesota
      Mayo Clinic Rochester
    2022-03-17
    Mar 17, 2022
    M
    Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
    Active, not recruiting
    • Plasma Cell Myeloma
    • Autologous Hematopoietic Stem Cell Transplantation
    • +2 more
    • Jacksonville, Florida
      Mayo Clinic in Florida
    2022-03-25
    Mar 25, 2022
    W
    Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
    Not yet recruiting
    • Glioblastoma
    • Daratumumab
    • Morgantown, West Virginia
      West Virginia University Cancer Institute Mary Babb Randolph Can
    2021-06-25
    Jun 25, 2021
    W
    Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
    Recruiting
    • Waldenstrom Macroglobulinemia
    • +6 more
    • New York, New York
      Weill Cornell Medicine
    2021-12-21
    Dec 21, 2021
    M
    Daratumumab to Treat Active Lupus Nephritis
    Recruiting
    • Lupus Nephritis
    • Daratumumab
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    2021-05-19
    May 19, 2021
    F
    Daratumumab in Treatment of PGNMID and C3 GN - 2020
    Completed
    Has Results
    • Membranoproliferative Glomerulonephritis
    • Daratumumab
    • Rochester, Minnesota
      Mayo Clinic
    2021-06-28
    Jun 28, 2021
    W
    Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
    Withdrawn
    • Multiple Myeloma
    • Dara-SC
    • +2 more
    • (no location specified)
    2022-01-06
    Jan 6, 2022
    I
    Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
    Recruiting
    • AL Amyloidosis
    • daratumumab and pomalidomide
    • Catanzaro, Italy
    • +2 more
    2021-06-23
    Jun 23, 2021
    W
    A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
    Recruiting
    • Multiple Myeloma
    • +2 more
    • Daratumumab
    • +3 more
    • New York, New York
      Weill Cornell Medicine - Multiple Myeloma Center
    2021-11-18
    Nov 18, 2021
    P
    Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
    Recruiting
    • Amyloidosis; Systemic
    • Daratumumab
    • +2 more
    • Beijing, China
      Peking Union Medical College Hospital
    2021-05-31
    May 31, 2021